Pfizer/Ligand Lasofoxifene Is First "Next-Generation" SERM Filed At FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer/Ligand’s lasofoxifene could be the first approved "next-generation" selective estrogen receptor modulator for osteoporosis.